Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206104240> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3206104240 abstract "Abstract Background Amiodarone may be used against ventricular arrhythmias to reduce ICD-shocks, and for rhythm control in patients with atrial fibrillation. The 2020 ESC atrial fibrillation guidelines upgraded the recommendation for amiodarone in rhythm control to class I, level of evidence A, although still with a caution to consider other antiarrhythmic drugs first. Amiodarone is the most potent antiarrhythmic drug in clinical use, but it has frequent and potentially severe side effects affecting several organ systems. We have seen an increasing number of patients with amiodarone-induced thyrotoxicosis. Purpose We wanted to study the prescription rate of amiodarone in Norway, which indications were most prevalent, and whether there had been any changes over time. Methods From the Norwegian Prescription Registry, we have collected data on how many patients had received amiodarone, and the number of defined daily doses delivered (DDDs), related to various reimbursement categories. Results From 2010 to 2019, the number of individuals receiving amiodarone from a pharmacy in Norway increased from 5359 to 7789 (45% increase), and the number of DDDs delivered from 994905 to 1412796 (42% increase) (Figure). With an atrial fibrillation-related reimbursement code, we found during the same period an increase of individuals from 3616 to 5776 (60% increase) and number of DDDs from 661531 to 1061601 (60% increase). The dispenses for ventricular arrhythmia-related reimbursement codes were close to unchanged during the same period of years (Figure). The fraction of amiodarone use related to atrial fibrillation increased from 66% in 2009 to 75% in 2019. Conclusion We observed a 42–45% increase in the total use of amiodarone over 10 years, and almost the whole increase was related to atrial fibrillation. In 2019, atrial fibrillation-related diagnoses accounted for 75% of the total amount of amiodarone dispensed in Norway. Due to the several side effects of amiodarone, we are concerned if the threshold for use of amiodarone diminishes. FUNDunding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Norwegian Institute of Public HealthOslo University Hospital, Rikshospitalet Number of patients Number of DDDs" @default.
- W3206104240 created "2021-10-25" @default.
- W3206104240 creator A5031092428 @default.
- W3206104240 creator A5043508416 @default.
- W3206104240 creator A5071529857 @default.
- W3206104240 date "2021-10-01" @default.
- W3206104240 modified "2023-09-26" @default.
- W3206104240 title "Increasing use of amiodarone in Norway" @default.
- W3206104240 doi "https://doi.org/10.1093/eurheartj/ehab724.0339" @default.
- W3206104240 hasPublicationYear "2021" @default.
- W3206104240 type Work @default.
- W3206104240 sameAs 3206104240 @default.
- W3206104240 citedByCount "0" @default.
- W3206104240 crossrefType "journal-article" @default.
- W3206104240 hasAuthorship W3206104240A5031092428 @default.
- W3206104240 hasAuthorship W3206104240A5043508416 @default.
- W3206104240 hasAuthorship W3206104240A5071529857 @default.
- W3206104240 hasConcept C104863432 @default.
- W3206104240 hasConcept C126322002 @default.
- W3206104240 hasConcept C160735492 @default.
- W3206104240 hasConcept C162324750 @default.
- W3206104240 hasConcept C164705383 @default.
- W3206104240 hasConcept C194828623 @default.
- W3206104240 hasConcept C2426938 @default.
- W3206104240 hasConcept C2778094803 @default.
- W3206104240 hasConcept C2778131192 @default.
- W3206104240 hasConcept C2779161974 @default.
- W3206104240 hasConcept C2779703844 @default.
- W3206104240 hasConcept C2780074459 @default.
- W3206104240 hasConcept C42219234 @default.
- W3206104240 hasConcept C50522688 @default.
- W3206104240 hasConcept C512399662 @default.
- W3206104240 hasConcept C71924100 @default.
- W3206104240 hasConcept C98274493 @default.
- W3206104240 hasConceptScore W3206104240C104863432 @default.
- W3206104240 hasConceptScore W3206104240C126322002 @default.
- W3206104240 hasConceptScore W3206104240C160735492 @default.
- W3206104240 hasConceptScore W3206104240C162324750 @default.
- W3206104240 hasConceptScore W3206104240C164705383 @default.
- W3206104240 hasConceptScore W3206104240C194828623 @default.
- W3206104240 hasConceptScore W3206104240C2426938 @default.
- W3206104240 hasConceptScore W3206104240C2778094803 @default.
- W3206104240 hasConceptScore W3206104240C2778131192 @default.
- W3206104240 hasConceptScore W3206104240C2779161974 @default.
- W3206104240 hasConceptScore W3206104240C2779703844 @default.
- W3206104240 hasConceptScore W3206104240C2780074459 @default.
- W3206104240 hasConceptScore W3206104240C42219234 @default.
- W3206104240 hasConceptScore W3206104240C50522688 @default.
- W3206104240 hasConceptScore W3206104240C512399662 @default.
- W3206104240 hasConceptScore W3206104240C71924100 @default.
- W3206104240 hasConceptScore W3206104240C98274493 @default.
- W3206104240 hasIssue "Supplement_1" @default.
- W3206104240 hasLocation W32061042401 @default.
- W3206104240 hasOpenAccess W3206104240 @default.
- W3206104240 hasPrimaryLocation W32061042401 @default.
- W3206104240 hasRelatedWork W1967892823 @default.
- W3206104240 hasRelatedWork W1969604802 @default.
- W3206104240 hasRelatedWork W1990523300 @default.
- W3206104240 hasRelatedWork W2012804304 @default.
- W3206104240 hasRelatedWork W2014195660 @default.
- W3206104240 hasRelatedWork W2039971474 @default.
- W3206104240 hasRelatedWork W2056922676 @default.
- W3206104240 hasRelatedWork W2416180887 @default.
- W3206104240 hasRelatedWork W3012508844 @default.
- W3206104240 hasRelatedWork W4213366160 @default.
- W3206104240 hasVolume "42" @default.
- W3206104240 isParatext "false" @default.
- W3206104240 isRetracted "false" @default.
- W3206104240 magId "3206104240" @default.
- W3206104240 workType "article" @default.